Survival of Patients With MBD4 -Mutated Metastatic Uveal Melanoma Treated With Immune Checkpoint Inhibitors
Translational Vision Science & Technology · 2026
DOI: 10.1167/tvst.15.9.19 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Vision Science & Technology, 2026. Verfasst von Natasha Honoré und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Institut Curie, Paris, France. Hauptthemen laut MEDLINE: Melanoma, Uveal Neoplasms, Mutation, Immune Checkpoint Inhibitors. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
The prognosis of metastatic uveal melanoma (mUM) remains poor, and immune checkpoint inhibitors (ICIs) show limited efficacy, with response rates typically below 5%. Tebentafusp, an immune therapy targeting the gp100 protein, is the first drug to improve overall survival (OS) in mUM. Somatic MBD4 deficiency induces a hypermutated phenotype in a fraction of UM cases and may predict benefit from ICIs.
Methods
We retrospectively analyzed patients with mUM carrying somatic or germline MBD4 alterations and treated with ICIs at Institut Curie (Paris, France). Clinical characteristics, treatments, and outcomes were collected.
Results
Twelve patients received ICIs (nine pembrolizumab, two ipilimumab + nivolumab, one pembrolizumab + lenvatinib). Most (83%) had M1a liver-only disease. The overall response rate was 50% (two complete, four partial) with a disease control rate of 83%. The median follow-up was 22 months (range, 9.9-116.8), and within this time frame median progression-free survival and OS were not reached. At 12 months, 73% of patients were progression free, and the estimated 2-year OS was 86%.
Conclusions
We observed that, in patients with MBD4-mutated mUM, ICIs achieved a 50% response rate and prolonged survival, demonstrating strong and sustained clinical activity in this distinct molecular subgroup and exceeding outcomes reported with ICIs or tebentafusp. Translational Relevance: Our findings support further evaluation of MBD4 mutation as a predictive biomarker and suggest that ICIs should be considered as a preferred first-line option in MBD4-mutated mUM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Institut Curie, Paris, France.
- Medical Oncology Department, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
- Somatic Genetic Unit, Department of Genetics, Institut Curie, PSL Research University, Paris, France.
- DRUM Team, INSERM U1339/UMR 3666, Institut Curie, Paris, France.
- Department of Medical Imaging, Institut Curie, PSL Research University, Paris, France.
- Department of Pathology, Institut Curie, PSL Research University, Institut Curie, Paris, France.
Zitieren
APA
Honoré, N., Sanchez, R., Piperno-Neumann, S., Pierron, G., Le Ven, A., Houy, A., Servois, V., Vincent-Salomon, A., Mariani, P., Cassoux, N., Matet, A., Ramtohul, T., Colas, C., & Rodrigues, M. (2026). Survival of Patients With MBD4 -Mutated Metastatic Uveal Melanoma Treated With Immune Checkpoint Inhibitors. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.15.9.19
Vancouver
Honoré N, Sanchez R, Piperno-Neumann S, Pierron G, Le Ven A, Houy A, et al. Survival of Patients With MBD4 -Mutated Metastatic Uveal Melanoma Treated With Immune Checkpoint Inhibitors. Translational Vision Science & Technology. 2026. doi:10.1167/tvst.15.9.19
BibTeX
@article{Honor2026,
author = {Honoré, Natasha and Sanchez, Raphaël and Piperno-Neumann, Sophie and Pierron, Gaëlle and Le Ven, Anaïs and Houy, Alexandre and Servois, Vincent and Vincent-Salomon, Anne and Mariani, Pascale and Cassoux, Nathalie and Matet, Alexandre and Ramtohul, Toulsie and Colas, Chrystelle and Rodrigues, Manuel},
title = {Survival of Patients With MBD4 -Mutated Metastatic Uveal Melanoma Treated With Immune Checkpoint Inhibitors},
journal = {Translational Vision Science & Technology},
year = {2026},
doi = {10.1167/tvst.15.9.19}
}
EUVIMED